Hoberman Kenneth
Hoberman Kenneth's purchase track record
Hoberman Kenneth has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/12/2022 | NVCT | $104K | -52.2% | -60.5% | +0.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
TGTX Highlighted as Affordable Biotech Growth Play. ChartMill recently featured TG Therapeutics as an affordable growth option within the biotech sector. This analysis suggests the stock may be viewed as undervalued relative to its potential, despite trading near its 52-week low. The mention adds a positive fundamental perspective to the current technical setup.
Transaction History
| NVCT | ▲ Buy | Grant | 35,000 | $0 | 6/11/2026 | View on chart |
| NVCT | ▲ Buy | Grant | 30,000 | $0 | 6/12/2025 | View on chart |
| TGTX | ▲ Buy | Grant | 14,718 | $0 | 6/12/2025 | View on chart |
| TGTX | ▲ Buy | Grant | 22,250 | $0 | 6/19/2024 | View on chart |
| NVCT | ▲ Buy | Grant | 30,000 | $0 | 6/13/2024 | View on chart |
| TGTX | ▲ Buy | Grant | 20,000 | $0 | 9/28/2023 | View on chart |
| NVCT | ▲ Buy | Grant | 18,000 | $0 | 6/16/2023 | View on chart |
| TGTX | ▲ Buy | Grant | 43,732 | $0 | 7/20/2022 | View on chart |
| NVCT | ▲ Buy | Open Market | 6,000 | $104K | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Nuvectis Pharma to speak at Maxim Growth Summit 2026
Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.
Nuvectis Pharma to speak at Maxim Growth Summit 2026. Nuvectis Pharma announced it will participate in the Maxim Growth Summit 2026. This corporate event provides an opportunity for the company to share updates with investors and analysts. Such appearances are standard for public companies seeking to maintain visibility in the market.